spacer
home > ict > winter 2019 > strategic success
PUBLICATIONS
International Clinical Trials

Strategic Success

ICT: With the addendum to the ICH E6 (R2) Guideline for Good Clinical Practice (GCP), the GCP has seen its first significant update in over 20 years. What is the new guideline and how does it impact clinical trial design?

Patrick Hughes: The ICH GCP Guidance Integrated Addendum provides a unified standard for the EU, Japan, the US, Canada, and Switzerland. The updated ICH E6 (R2) guidelines have been introduced to encourage the implementation of improved and more efficient approaches to clinical trial design, conduct, oversight, recording, and reporting, while continuing to ensure human subject protection and reliability of trial results. Far from being considered a hurdle to overcome, the ICH E6 (R2) should be a positive step forward and an exciting opportunity for more efficient clinical R&D, with significantly better outcomes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Patrick Hughes is the Chief Commercial Officer at CluePoints. He holds a marketing degree from Newcastle University, UK, and a postgraduate marketing diploma in B2B marketing strategy from the Kellogg School of Management, US. Responsible for leading global sales, product, marketing, operational, and technical teams throughout his career, Patrick is a Senior Executive with over eighteen years of international commercial experience within life sciences, healthcare, and telecommunications.
spacer
Patrick Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

HemaCare and Tissue Solutions Announce Strategic Partnership to Expand Access to Human Disease-State Samples

HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, and Tissue Solutions Ltd, a leading global provider of diseased human biosamples for research, today announced their partnership to supply customers with an expanded selection of well-qualified disease-state biomaterials in fresh, frozen, and FFPE formats.
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 
Industry Events

Respiratory Drug Delivery (RDD®) Europe 2019

7-10 May 2019, Estoril Congress Center, Lisbon

Respiratory Drug Delivery (RDD®) Europe 2019 connects emerging and high-level scientists, academics, industrial and regulatory specialists, and clinicians. It is a must-attend conference for companies involved in research, development, testing or marketing of medicines, devices and services associated with pulmonary or nasal pharmaceutical products. This year, RDD Europe 2019 will be held in Estoril (Lisbon), Portugal, May 7-10, 2019, and, as in previous years is jointly organized by RDD Online and Aptar Pharma.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement